Please login to the form below

Not currently logged in
Email:
Password:

Robocath appoints CEO

Pascal Guy promoted at medical robotics start-up

Robocath Pascal GuyRouen, France-based Robocath, a medical robotics start-up specialising in endovascular procedures, has formerly appointed Pascal Guy as its new chief executive officer.

Guy first joined Robocath in 2015 as a consultant, and has since gradually assumed the role of chief executive. He will now oversee the clinical development and rollout of the R-One robot, as well as work to consolidate the firm's intellectual property and assets.

He brings over 20 years of medtech experience to the start-up, most recently at US firm Stryker Neurovascular, where he served as international vice president.

Prior to this, Guy was global vice president of sales and marketing for Europe and Japan with the Sorin Group, and worked at Boston Scientific from 1996 to 2007.

Philippe Bencteux, founder and president of Robocath, said: “We are delighted to welcome Pascal Guy in this strategic management position, especially since Robocath is currently at a pivotal moment in its development.

"Thanks to his wealth of experience working with vascular medical devices in some of the leading companies, he will bring to Robocath his strategic management skills, his understanding of the needs of the sector and his up-to-date knowledge of the market.”

4th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Globe
Rare diseases: meeting the challenge
Problems with regulating orphan drugs...
Digital storytelling means building the story around data
The value of digital storytelling in pharma lies in its ability to convert facts and figures into compelling content for patients and HCPs....
Pharma and free medicines: a different perspective
Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients....

Infographics